首页> 外文期刊>The journal of clinical psychiatry >Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients.
【24h】

Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients.

机译:社区精神病学治疗机构中持久性抗精神病药合用和过量给药:对435名加拿大门诊患者的用药情况进行了回顾。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: The present study aimed (1) to determine the proportion of patients treated with persistent antipsychotic polypharmacy in an outpatient population and (2) to determine if persistent antipsychotic polypharmacy is associated with excessive dosing. METHOD: Using a province-wide network that links all pharmacies in British Columbia, Canada, to a central set of data systems, we identified community mental health outpatients who had been treated with the same pharmacologic regimen for at least 90 days. Apart from antipsychotics, data collection included anticholinergics, antidepressants, mood stabilizers, benzodiazepines, lipid-lowering agents, and antidiabetic agents. Demographic data including sex, age, and diagnosis were obtained from the patient's chart. In order to compare dosages of the various antipsychotics we used a fixed unit of measurement based on dividing the prescribed daily dose (PDD) by the defined daily dose (DDD). A PDD/DDD ratio greater than 1.5 was defined as excessive dosing. RESULTS: Four hundred thirty-five patients met the inclusion criteria and were included in the analysis. Overall, the prevalence of persistent antipsychotic polypharmacy was 25.7% for the entire cohort. The prevalence of persistent antipsychotic polypharmacy was highest for patients with schizoaffective disorder (33.7%), followed by schizophrenia (31.7%), psychosis not otherwise specified (20.0%), bipolar disorder (16.9%), and major depression (14.3%). The mean +/- SD PDD/DDD ratio for all patients prescribed persistent antipsychotic polypharmacy was not only excessive, it was significantly greater compared to that of patients receiving antipsychotic monotherapy (1.94 +/- 0.12 vs 0.94 +/- 0.04, P < .005). CONCLUSIONS: Using a diagnostically heterogeneous outpatient population, this study is, we believe, the first to report that persistent antipsychotic polypharmacy is associated with excessive dosing, in and of itself as well as compared to antipsychotic monotherapy.
机译:目的:本研究旨在(1)确定在门诊患者中接受持续抗精神病药物治疗的患者比例,以及(2)确定持续抗精神病药物治疗是否与过量用药有关。方法:使用将加拿大不列颠哥伦比亚省的所有药房链接到一个中央数据系统的省级网络,我们确定了接受相同药物治疗至少90天的社区心理健康门诊患者。除抗精神病药外,数据收集还包括抗胆碱能药,抗抑郁药,情绪稳定剂,苯二氮卓类药物,降脂药和抗糖尿病药。包括性别,年龄和诊断的人口统计学数据是从患者图表中获得的。为了比较各种抗精神病药的剂量,我们使用固定的计量单位,以规定的日剂量(PDD)除以定义的日剂量(DDD)为基础。 PDD / DDD比率大于1.5的情况被定义为剂量过大。结果:435例患者符合入选标准,并纳入分析。总体而言,在整个队列中,持续使用抗精神病药物的比例为25.7%。患有分裂情感障碍的患者持续服用抗精神病药的比例最高(33.7%),其次是精神分裂症(31.7%),未另作说明的精神病(20.0%),躁郁症(16.9%)和严重抑郁症(14.3%)。所有开具持续抗精神病药物治疗的患者的平均+/- SD PDD / DDD比率不仅过高,而且比接受抗精神病药物单一疗法的患者的平均+/- SD PDD / DDD比率显着更高(1.94 +/- 0.12 vs 0.94 +/- 0.04,P <。 005)。结论:我们认为,这项研究使用诊断异质性门诊患者,是第一个报告说,与抗精神病药物单一疗法相比,持久性抗精神病药物合用与过量用药有关,其本身以及与之相关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号